NCT04839744View on ClinicalTrials.gov

A Comparative Study of TG103 Produced by Two Manufacturing Processes in Chinese Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 18, 2021

Primary Completion Date

June 15, 2021

Study Completion Date

July 2, 2021

Conditions
Healthy Male Subjects
Interventions
DRUG

TG103 produced by the modified manufacturing process

Drug: TG103 (a modified manufacturing process), 15mg, SC

DRUG

TG103 produced by the original manufacturing process

Drug: TG103 (the original manufacturing process), 15mg, SC

Trial Locations (1)

210008

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing

All Listed Sponsors
lead

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

INDUSTRY